Media not available due to technical recording problems. EVRS is very sorry for the inconvenience.



Vitreomacular interface changes of AMD patients such as posterior vitreous detachment (PVD), vitreomacular adhesion (VMA) and vitreomacular traction (VMT) have been addressed in several clinical studies using optic coherence tomography (OCT).However role of epiretinal membrane (ERM) has not been investigated in the concept of vitreomacular interface disorders in nAMD patients.

Methods or Study Design:

This study is a retrospective observational case series and was conducted at the Gazi University School of Medicine, Ankara, Turkey. The reports of the patients with a diagnosis of new-onset nAMD who were at least 50 years old and treated with intravitreal anti-VEGFs (ranibizumab or bevacuzimab) between October 2010 and September 2013 in our retina clinic, were reviewed for the vitreomacular interface changes.


The study included 110 eyes of 110 nAMD patients. The mean age of the patients was 70 ± 7.8, with 46 (41.8%) being male and 64 (58.2%) being female. According to the examinations with OCT and B-mode ultrasonography (USG), 50 patients had ‘concurrent’ 11VMA (32 focal, 18 broad;group 1).37 patients had complete PVD (group 2) and 21 patients (group 3) had epiretinal membrane.The number of injections was highest for the patients with epiretinal membrane (group 3) and this difference was statistically significant (p<0.001). The mean interval between injections and the mean longest interval were shorter in group 3 (p<0.05).


Presence of ERM in association with nAMD seems to increase the number of anti-VEGF injections and decrease the injection intervals for the treatment of nAMD. Although the anatomical and functional results are similar in eyes with or without ERM, the increased need for anti-VEGFs may mean that these membranes may decrease the penetration of the drugs through these membranes, which may act as a physical barrier.